NEI Research News

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).

In October 2009, the FDA, the National Eye Institute, and the Department of Defense launched the LASIK Quality of Life Collaboration Project.

More than 72,000 clinical photographs illustrate age-related eye disease progression

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

Los investigadores determinaron que los latinos presentan mayores índices de deterioro visual, ceguera, enfermedad diabética del ojo y cataratas que los blancos no hispanos.

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos.

Researchers have shown that ranibizumab eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina.

A large genetic study of age-related macular degeneration (AMD) has identified three new genes associated with this blinding eye disease-two involved in the cholesterol pathway.

Scientists have shown that through an eye exam, doctors can identify infants who are most likely to benefit from early treatment for a potentially blinding eye condition called retinopathy of prematurity (ROP), resulting in better vision for many children

The National Eye Institute mourns the loss of M. Velma Dobson, Ph.D., a long-time advisor and expert on NEI clinical research studies in infants and children. She passed away on Friday, April 9 from Lou Gehrig’s disease.